SCHEMBL8375398

SCHEMBL8375398

O=C(Oc1c(Br)cc(Br)cc1C(=O)O)c1cc(C(=O)Oc2c(Br)cc(Br)cc2C(=O)O)cc(C(=O)Oc2c(Br)cc(Br)cc2C(=O)O)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 2/20 0.62
▸ AKR1C3 P42330 2/20 0.50
▸ AKR1C2 P52895 2/20 0.50
▸ AKR1C1 Q04828 2/20 0.50
▸ AKR1C4 P17516 1/20 0.50
▸ GPR35 Q9HC97 4/20 0.41
▸ KDM4E B2RXH2 1/20 0.37
▸ GLA P06280 1/20 0.37
▸ TPMT P51580 1/20 0.37
▸ MEN1 O00255 2/20 0.36
▸ LMNA P02545 2/20 0.36
▸ HTT P42858 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ MAPT P10636 1/20 0.36
▸ NOD2 Q9HC29 1/20 0.36
▸ LCK P06239 1/20 0.36
▸ FYN P06241 1/20 0.36
▸ CFD P00746 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ POLA1 P09884 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8044565 0.95 HSD17B10 (0.57) HSD17B10AKR1C3AKR1C2AKR1C1AKR1C4
SCHEMBL4318333 0.81 HSD17B10 (0.69) HSD17B10AKR1C3AKR1C2AKR1C1AKR1C4
SCHEMBL9174491 0.80 HSD17B10 (0.43) HSD17B10AKR1C3AKR1C2AKR1C1AKR1C4
SCHEMBL7813490 0.77 HSD17B10 (1.00) HSD17B10AKR1C3AKR1C2AKR1C1AKR1C4
SCHEMBL8374273 0.75 HSD17B10 (0.39) HSD17B10AKR1C3AKR1C2AKR1C1AKR1C4
SCHEMBL9173276 0.75 HTT (0.47) HSD17B10KDM4EMEN1LMNAHTT
SCHEMBL8372308 0.74 HSD17B10 (0.59) HSD17B10AKR1C3AKR1C2AKR1C1AKR1C4
SCHEMBL8541393 0.72 HSD17B10 (0.67) HSD17B10AKR1C3AKR1C2AKR1C1AKR1C4
SCHEMBL8056715 0.72 HSD17B10 (0.67) HSD17B10AKR1C3AKR1C2AKR1C1AKR1C4
SCHEMBL8372180 0.70 POLB (0.35) HSD17B10KDM4ETPMTMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0669940-B1 SPECIFICALLY CROSSLINKED HEMOGLOBIN WITH FREE FUNCTIONALITY UNIV TORONTO (CA) 1999-02-10 — — EP claimed
US-11298407-B2 Hemoglobin based oxygen carrier and method of preparation THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2022-04-12 — — US disclosed
WO-2018053634-A1 HEMOGLOBIN BASED OXYGEN CARRIER AND METHOD OF PREPARATION THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2018-03-29 — — WO disclosed
WO-2017197499-A1 STABILIZED HEMOGLOBIN-AVIDIN ASSEMBLY AND METHOD OF PREPARATION THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2017-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11298407-B2 Hemoglobin based oxygen carrier and method of preparation HBZ, HBB, HBG2 HSD17B10 2382/4885AKR1C3 867/4885AKR1C2 651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback